title: B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen.
abstract: Non-Hodgkin lymphoma associated with pregnancy is rare. Rituximab based chemotherapy is now considered the standard of care and considered safe for the treatment of diffuse large B-cell lymphoma (DLBCL) during pregnancy but little is known about its safety profile on the fetus. A 32 y primigravida was diagnosed as DLBCL at 20 wk of gestation. She received rituximab containing chemotherapy with successful pregnancy outcome. Though the baby was absolutely healthy, B-cell was totally absent in the cord blood.
authors.affiliation: Department of Hematology, NRS Medical College and Hospital, 138, AJC Bose Road, Kolkata, 700014, India.
authors.forename: Prakas Kumar
authors.initials: PK
authors.lastname: Mandal
authors.forename: Tuphan Kanti
authors.initials: TK
authors.lastname: Dolai
authors.forename: Basab
authors.initials: B
authors.lastname: Bagchi
authors.forename: Malay Kumar
authors.initials: MK
authors.lastname: Ghosh
authors.forename: Sudipta
authors.initials: S
authors.lastname: Bose
authors.forename: Maitreyee
authors.initials: M
authors.lastname: Bhattacharyya
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects*; D005260:Female; D005312:Fetal Blood / Q000166:cytology*; D006801:Humans; D007231:Infant, Newborn; D018655:Lymphocyte Count; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D000069283:Rituximab / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D000069283:Rituximab